Measuring Oncological Value of Exercise and Statin

• Status: Not yet recruiting
• Trial end date: 2027-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tampere University Hospital
• Collaborators: Aalto University; Tampere University; University of Helsinki; University of Turku
• Treatments: Atorvastatin

Criteria

Inclusion Criteria:

• The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started

• Prostate cancer: First course of docetaxel treatment for metastatic prostate cancer.

• Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status.

• Kidney cancer: medium-risk/high-risk kidney cancer according to the IMDC classification, for which 1st-line cancer drug treatment is started as tki monotherapy or as a combination treatment that includes tki medication. - the randomization of subjects is stratified according to gender

• Ovarian cancer: stage III or IV cancer for which 1st-line chemotherapy treatment is started.

• The patient agrees to the study and signs a written informed consent.

• Adult (18 years=>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study.

• In women, the use of a reliable contraceptive during the intervention

Exclusion Criteria:

• High risk of bone fractures

• Inability to physical exertion and/or unsuitability for cancer drug treatment

• Poor co-operation ability for psychological reasons

• Active use of cholesterol-lowering drugs

• Severe liver or kidney failure

• Troublesome side effects that occurred in the past during cholesterol medication

• Continuous use of medicinal substances that interact with atorvastatin during the study period

• A special group of subjects according to the Medical Research Act (1999/488) (e.g. minors and pregnant or lactating women)